Latest Conference Articles

October 22nd 2015, 6:05am

ASTRO Annual Meeting

The use of radiation therapy has declined despite evidence demonstrating it is often more beneficial than single-agent chemotherapy or observation-alone in patients with low-grade follicular lymphoma.

October 21st 2015, 3:12pm

International Thyroid Congress

Pablo Valderrabano, MD, Clinical Research Fellow at Moffitt Cancer Center, discusses molecular markers in thyroid nodules and their connection to cancer incidence.

October 21st 2015, 2:02pm

International Thyroid Congress

Aditi Kumar, MD, endocrinology fellow at the University of Mississippi, discusses aggressive multimodal therapy in anaplastic thyroid cancer. A study conducted at the Mayo Clinic, where Kumar was previously a fellow, looked at 29 patients with stage IV, A, B and C anaplastic thyroid cancer, a rare form of thyroid cancer with poor outcomes. Often, patients are not treated at this stage, as options are limited and toxicities from treatments can be high, says Kumar.

October 21st 2015, 12:37pm

International Thyroid Congress

The oral multikinase inhibitor cabozantinib showed promise as a second- or third-line therapy in patients with advanced radioactive iodine-refractory differentiated thyroid cancer.

October 21st 2015, 11:19am

International Thyroid Congress

The progression-free survival benefit with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer was observed across common sites of metastasis.

October 21st 2015, 9:48am

International Thyroid Congress

A large survey of endocrinologists found wide variation in management strategies for thyroid nodules that were frequently misaligned with current guidelines, particularly for biopsies by fine-needle aspiration.

October 20th 2015, 3:08pm

International Thyroid Congress

Umamaheswar Duvvuri, MD, PhD, Assistant Professor of Otolaryngology (ENT) at the University of Pittsburgh Medical Center, talks about potential genetic signatures for locally advanced, well differentiated thyroid cancers.

October 20th 2015, 2:20pm

International Thyroid Congress

Manisha Shah, MD, Professor of Oncology at Ohio State University Medical Center, College of Medicine discusses cabozantinib in patients with radioiodine- refractory differentiated thyroid cancer.

October 17th 2015, 9:46am

NANETS Symposium

Pamela L. Kunz, MD, assistant professor of Medicine (Oncology), Stanford University School of Medicine, discusses the potential of immunotherapy in the treatment of patients with neuroendocrine tumors (NETs).

October 17th 2015, 9:40am

NANETS Symposium

Everolimus improved progression-free survival by 7.1 months compared with placebo in patients with lung/gastrointestinal (GI) neuroendocrine tumors, representing a 52% reduction in the risk of progression or death.

October 17th 2015, 8:15am

NANETS Symposium

Lu-Dotatate demonstrated an unprecedented 79% reduction in the risk of progression or death compared with high-dose octreotide LAR in patients with progressive, metastatic midgut neuroendocrine tumors.

October 17th 2015, 8:12am

NANETS Symposium

James C. Yao, MD, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses results of the RADIANT-4 study, which examined the safety and efficacy of everolimus in advanced nonfunctional neuroendocrine tumors (NETs) of lung or gastrointestinal origin.

October 16th 2015, 3:39pm

NANETS Symposium

Lowell B. Anthony, MD, professor of Medicine, University of Kentucky, discusses patient exit interviews from the phase III placebo-controlled TELESTAR trial, which evaluated telotristate epitrate in patients with inadequately controlled carcinoid syndrome.

October 16th 2015, 3:17pm

NANETS Symposium

Telotristat etiprate, a novel serotonin synthesis inhibitor, helped reduce daily bowel movements for patients with carcinoid syndrome no longer responding to standard-of-care therapies.

October 16th 2015, 2:22pm

NANETS Symposium

Combining the chemotherapy streptozotocin with drugs that target the mTOR pathway may be an effective way to treat pancreatic neuroendocrine tumors.

October 16th 2015, 12:54pm

NANETS Symposium

The efficacy of several predictive markers previously thought to determine which patients might respond to temozolomide-based therapy could not be validated for patients with pancreatic neuroendocrine tumors.

October 16th 2015, 12:12pm

NANETS Symposium

Jonathan R. Strosberg, MD, medical oncologist, Department of Gastrointestinal Oncology, section head, Neuroendocrine Division, chair, Gastrointestinal Department Research Program, Moffitt Cancer Center, discusses results of the phase III NETTER-1 trial for midgut neuroendocrine tumors.

October 16th 2015, 11:53am

NANETS Symposium

Full surgical resection of gastroenteropancreatic neuroendocrine tumors is associated with a greater than 90% survival rate at five years.

October 16th 2015, 6:29am

NANETS Symposium

Eric Liu, MD, FACS, surgeon, neuroendocrine tumors, Rocky Mountain Cancer Centers, discusses some of the most recent medical advancements in the field of neuroendocrine tumors.

October 16th 2015, 5:30am

NANETS Symposium

David C. Metz, MD, gastroenterologist, University of Pennsylvania School of Medicine, associate chief, Medical Affairs, Division of Gastroenterology, discusses the increasing incidence of neuroendocrine tumors.